Oxcia’s CEO Ulrika Warpman Berglund created large interest with the poster presentation of the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects at the 6th Annual DDR Inhibitors Summit in Boston. The conference gave a comprehensive overview of the DDR space (DDR is short for DNA Damage Response – and refers to the processes the body uses to repair the damage that occurs to DNA), with many world class speakers sharing preclinical and clinical updates as well as discussing combination studies with DDR inhibitors, possible solutions to improving patient selection and overcoming the large toxicity problem. Oxcia’s OXC-101 has several advantages in these areas. It is believed to be effective, in mono and combination therapy, for a large target patient population and be well-tolerated. Finding the treatment alternative with the best therapeutic index (the highest benefit with lowest toxicity) is the ultimate goal.